Frequently Asked Question
The global recombinant cell culture supplements market was valued at USD 0.4 Billion in 2022.
The recombinant cell culture supplements market is expected to grow at a CAGR of 9.50% between 2023 and 2030, reaching USD 0.8 Billion in 2030.
Recombinant albumin category is the leading segment by product, holding over 20% share in terms of value in 2022.
The regenerative medicine segment governs the demand for recombinant cell culture supplements in the world, holding a massive share of over 53% in 2022.
The mammalian expression system segment is expected to post the highest CAGR during the forecast period.
North America is fueling the growth of the recombinant cell culture supplements industry, with over one-third share in 2022.
The top players include Abcam plc., Corning Incorporated, BBI Solutions OEM Limited, FUJIFILM Irvine Scientific, Inc., Gemini Bioproducts, LLC, HiMedia Laboratories, LLC, Kingfisher Biotech, Inc., Lonza Group AG, Merck KGaA, Novus Biologicals, LLC, and ThermoFisher Scientific.
In the upcoming years, the market for recombinant cell culture supplements is anticipated to expand as a result of factors including developing cell culture technology and rising funding for biopharmaceutical research.
A significant obstacle is the high cost of supplements for recombinant cell cultures. These supplements are frequently expensive to create, which raises the cost to consumers. This may reduce the market potential for these goods, especially in developing nations where healthcare spending may be more limited.
One of the key opportunities in the recombinant cell culture supplements market is the rising need for immunotherapy, stem cell, and regenerative medicine research.